Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

British Journal of Haematology

Volumn 164, Issue 3, 2014, Pages 366-375

  Uttenthal, Benjamin ^a   Martinez Davila, Irma ^a   Ivey, Adam ^b   Craddock, Charles ^c   Chen, Frederick ^c   Virchis, Andras ^d   Kottaridis, Panagiotis ^e   Grimwade, David ^b   Khwaja, Asim ^f   Stauss, Hans ^a   Morris, Emma C ^a,e,f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Immunotherapy; Trials; Tumour antigens

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; MESSENGER RNA; PAN HLA DR ANTIGEN HELPER CELL EPITOPE; PROTEIN WT126; PROTEIN WT235; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER IMMUNIZATION; CANCER RISK; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; DRUG DOSE ESCALATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; LYMPHOCYTE FUNCTION; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE MYELOID LEUKAEMIA; IMMUNOTHERAPY; TRIALS; TUMOUR ANTIGENS;

AGED; CANCER VACCINES; EPITOPES; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; WT1 PROTEINS;

EID: 84892486302     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12637     Document Type: Article

References (49)

1. Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H.M., Kubo, R.T. & Sette, A. (1994) Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity, 1, 751-761.
2. Algar, E.M., Khromykh, T., Smith, S.I., Blackburn, D.M., Bryson, G.J. & Smith, P.J. (1996) A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene, 12, 1005-1014.
3. Baird, P.N. & Simmons, P.J. (1997) Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Experimental Hematology, 25, 312-320.
4. Bellantuono, I., Gao, L., Parry, S., Marley, S., Dazzi, F., Apperley, J., Goldman, J.M. & Stauss, H.J. (2002) Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood, 100, 3835-3837.
5. Bijker, M.S., van den Eeden, S.J.F., Franken, K.L., Melief, C.J.M., Offringa, R. & van der Bur, S.H. (2007) CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. Journal of Immunology (Baltimore, Md.: 1950), 179, 5033-5040.
6. Call, K.M., Glaser, T., Ito, C.Y., Buckler, A.J., Pelletier, J., Haber, D.A., Rose, E.A., Kral, A., Yeger, H. & Lewis, W.H. (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell, 60, 509-520.
7. Cilloni, D., Gottardi, E., Messa, F., Fava, M., Scaravaglio, P., Bertini, M., Girotto, M., Marinone, C., Ferrero, D., Gallamini, A., Levis, A. & Saglio, G. (2003) Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. Journal of Clinical Oncology, 21, 1988-1995.
8. Cilloni, D., Renneville, A., Hermitte, F., Hills, R.K., Daly, S., Jovanovic, J.V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., Izzo, B., Nomdedeu, J., van der Heijden, A., van der Reijden, B.A., Jansen, J.H., van der Velden, V.H.J., Ommen, H., Preudhomme, C., Saglio, G. & Grimwade, D. (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European Leukemia Net study. Journal of Clinical Oncology, 27, 5195-5201.
9. Dutoit, V., Rubio-Godoy, V., Dietrich, P.Y., Quiqueres, A.L., Schnuriger, V., Rimoldi, D., Liénard, D., Speiser, D., Guillaume, P., Batard, P., Cerottini, J.C., Romero, P. & Valmori, D. (2001) Heterogeneous T-cell response to MAGE-A10 (254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Research, 61, 5850-5856.
10. Gabert, J., Beillard, E., van der Velden, V.H.J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J.M., Cavé, H., Pane, F., Aerts, J.L.E., De Micheli, D., Thirion, X., Pradel, V., González, M., Viehmann, S., Malec, M., Saglio, G. & van Dongen, J.J.M. (2003) Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 17, 2318-2357.
11. Gannagé, M., Abel, M., Michallet, A.-S., Delluc, S., Lambert, M., Giraudier, S., Kratzer, R., Niedermann, G., Saveanu, L., Guilhot, F., Camoin, L., Varet, B., Buzyn, A. & Caillat-Zucman, S. (2005) Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. Journal of Immunology (Baltimore, Md.: 1950), 174, 8210-8218.
12. Gao, L., Bellantuono, I., Elsasser, A., Marley, S.B., Gordon, M.Y., Goldman, J.M. & Stauss, H.J. (2000) Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood, 95, 2198-2203.
13. Gao, L., Xue, S.-A., Hasserjian, R., Cotter, F., Kaeda, J., Goldman, J.M., Dazzi, F. & Stauss, H.J. (2003) Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation, 75, 1429-1436.
14. Gillmore, R., Xue, S.-A., Holler, A., Kaeda, J., Hadjiminas, D., Healy, V., Dina, R., Parry, S.C., Bellantuono, I., Ghani, Y., Coombes, R.C., Waxman, J. & Stauss, H.J. (2006) Detection of Wilms' tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clinical Cancer Research, 12, 34-42.
15. Goldman, J.M., Gale, R.P., Horowitz, M.M., Biggs, J.C., Champlin, R.E., Gluckman, E., Hoffmann, R.G., Jacobsen, S.J., Marmont, A.M. & McGlave, P.B. (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Annals of Internal Medicine, 108, 806-814.
16. Gorello, P., Cazzaniga, G., Alberti, F., Dell'Oro, M.G., Gottardi, E., Specchia, G., Roti, G., Rosati, R., Martelli, M.F., Diverio, D., Lo Coco, F., Biondi, A., Saglio, G., Mecucci, C. & Falini, B. (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia, 20, 1103-1108.
17. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringdén, O., Rozman, C. & Speck, B. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555-562.
18. Inoue, K., Ogawa, H., Sonoda, Y., Kimura, T., Sakabe, H., Oka, Y., Miyake, S., Tamaki, H., Oji, Y., Yamagami, T., Tatekawa, T., Soma, T., Kishimoto, T. & Sugiyama, H. (1997) Aberrant over expression of the Wilms Tumor gene (WT1) in human leukemia. Blood, 89, 1405-1412.
19. Janssen, E.M., Droin, N.M., Lemmens, E.E., Pinkoski, M.J., Bensinger, S.J., Ehst, B.D., Griffith, T.S., Green, D.R. & Schoenberger, S.P. (2005) CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature, 434, 88-93.
20. Kast, W.M., Brandt, R.M. & Melief, C.J. (1993) Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination. European Journal of Immunology, 23, 1189-1192.
21. Keilholz, U., Weber, J., Finke, J.H., Gabrilovich, D.I., Kast, W.M., Disis, M.L., Kirkwood, J.M., Scheibenbogen, C., Schlom, J., Maino, V.C., Lyerly, H.K., Lee, P.P., Storkus, W., Marincola, F., Worobec, A. & Atkins, M.B. (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. Journal of Immunotherapy (Hagerstown, Md.: 1997), 25, 97-138.
22. Keilholz, U., Letsch, A., Busse, A., Asemissen, A.M., Bauer, S., Blau, I.W., Hofmann, W.-K., Uharek, L., Thiel, E. & Scheibenbogen, C. (2009) A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood, 113, 6541-6548.
23. King, J.W., Thomas, S., Corsi, F., Gao, L., Dina, R., Gillmore, R., Pigott, K., Kaisary, A., Stauss, H.J. & Waxman, J. (2009) IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer. Clinical Cancer Research, 15, 1145-1154.
24. Kuball, J., de Boer, K., Wagner, E., Wattad, M., Antunes, E., Weeratna, R.D., Vicari, A.P., Lotz, C., van Dorp, S., Hol, S., Greenberg, P.D., Heit, W., Davis, H.L. & Theobald, M. (2011) Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with Montanide ISA51 and CpG7909. Cancer Immunology, Immunotherapy: CII, 60, 161-171.
25. Maslak, P.G., Dao, T., Krug, L.M., Chanel, S., Korontsvit, T., Zakhaleva, V., Zhang, R., Wolchok, J.D., Yuan, J., Pinilla-Ibarz, J., Berman, E., Weiss, M., Jurcic, J., Frattini, M.G. & Scheinberg, D.A. (2010) Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood, 116, 171-179.
26. Menssen, H.D., Renkl, H.J., Entezami, M. & Thiel, E. (1997) Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood, 89, 3486-3487.
27. Miyoshi, Y., Ando, A. & Egawa, C. (2002) High expression of Wilms 'Tumor suppressor gene predicts poor prognosis in breast cancer patients. Clinical Cancer Research, 8, 1167-1171.
28. Mundlos, S., Pelletier, J., Darveau, A., Bachmann, M., Winterpacht, A. & Zabel, B. (1993) Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development (Cambridge, England), 119, 1329-1341.
29. Nugent, C.T., Morgan, D.J., Biggs, J.A., Ko, A., Pilip, I.M., Pamer, E.G. & Sherman, L.A. (2000) Characterization of CD8+ T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas. Journal of Immunology (Baltimore, Md.: 1950), 164, 191-200.
30. Odom, L., Githens, J., Morse, H., Sharma, B., August, C., Humbert, J., Peakman, D., Rusnak, S. & Johnson, F. (1978) Remission of relapsed leukæmia during a graft-versus-host reaction a "graft-versus-leukæmia reaction" in man? The Lancet, 312, 537-540.
31. Oji, Y., Miyoshi, S., Maeda, H., Hayashi, S., Tamaki, H., Nakatsuka, S.-I., Yao, M., Takahashi, E., Nakano, Y., Hirabayashi, H., Shintani, Y., Oka, Y., Tsuboi, A., Hosen, N., Asada, M., Fujioka, T., Murakami, M., Kanato, K., Motomura, M., Kim, E.H., Kawakami, M., Ikegame, K., Ogawa, H., Aozasa, K., Kawase, I. & Sugiyama, H. (2002) Over expression of the Wilms' tumor gene WT1 in de novo lung cancers. International Journal of Cancer, 100, 297-303.
32. Oka, Y., Tsuboi, A., Murakami, M., Hirai, M., Tominaga, N., Nakajima, H., Elisseeva, O.A., Masuda, T., Nakano, A., Kawakami, M., Oji, Y., Ikegame, K., Hosen, N., Udaka, K., Yasukawa, M., Ogawa, H., Kawase, I. & Sugiyama, H. (2003) Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. International Journal of Hematology, 78, 56-61.
33. Oka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O.A., Oji, Y., Kawakami, M., Ikegame, K., Hosen, N., Yoshihara, S., Wu, F., Fujiki, F., Murakami, M., Masuda, T., Nishida, S., Shirakata, T., Nakatsuka, S.-I., Sasaki, A., Udaka, K., Dohy, H., Aozasa, K., Noguchi, S., Kawase, I. & Sugiyama, H. (2004) Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proceedings of the National Academy of Sciences of the United States of America, 101, 13885-13890.
34. Ramani, P. & Cowell, J.K. (1996) The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours. The Journal of Pathology, 179, 162-168.
35. Rezvani, K., Grube, M., Brenchley, J.M., Sconocchia, G., Fujiwara, H., Price, D.A., Gostick, E., Yamada, K., Melenhorst, J., Childs, R., Hensel, N., Douek, D.C. & Barrett, A.J. (2003) Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood, 102, 2892-2900.
36. Rezvani, K., Brenchley, J.M., Price, D.A., Kilical, Y., Gostick, E., Sewell, A.K., Li, J., Mielke, S., Douek, D.C. & Barrett, A.J. (2005) T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clinical Cancer Research, 11, 8799-8807.
37. Rezvani, K., Yong, A.S.M., Mielke, S., Savani, B.N., Musse, L., Superata, J., Jafarpour, B., Boss, C. & Barrett, A.J. (2008) Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood, 111, 236-242.
38. Rezvani, K., Yong, A.S.M., Mielke, S., Jafarpour, B., Savani, B.N., Le, R.Q., Eniafe, R., Musse, L., Boss, C., Kurlander, R. & Barrett, A.J. (2011) Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica, 96, 432-440.
39. Rosato, A., Zoso, A., Santa, S.D., Milan, G., Del Bianco, P., De Salvo, G.L. & Zanovello, P. (2006) Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8+ T cell parameters. Journal of Immunology, 176, 1999-2006.
40. Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., Ozawa, H., Wake, A., Taniguchi, S., Shultz, L.D., Ohara, O. & Ishikawa, F. (2010) Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Science Translational Medicine, 2, 17ra9.
41. Scheibenbogen, C., Letsch, A., Thiel, E., Schmittel, A., Mailaender, V., Baerwolf, S., Nagorsen, D. & Keilholz, U. (2002) CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood, 100, 2132-2137.
42. Theobald, M., Biggs, J., Hernández, J., Lustgarten, J., Labadie, C. & Sherman, L.A. (1997) Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. The Journal of Experimental Medicine, 185, 833-841.
43. Tsuboi, A., Oka, Y., Osaki, T., Kumagai, T., Tachibana, I., Hayashi, S., Murakami, M., Nakajima, H., Elisseeva, O.A., Fei, W., Masuda, T., Yasukawa, M., Oji, Y., Kawakami, M., Hosen, N., Ikegame, K., Yoshihara, S., Udaka, K., Nakatsuka, S.-I., Aozasa, K., Kawase, I. & Sugiyama, H. (2004) WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiology and Immunology, 48, 175-184.
44. Tsuboi, A., Oka, Y., Kyo, T., Katayama, Y., Elisseeva, O.A., Kawakami, M., Nishida, S., Morimoto, S., Murao, A., Nakajima, H., Hosen, N., Oji, Y. & Sugiyama, H. (2011) Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia, 26, 1410-1413.
45. Turner, M.J., Jellison, E.R., Lingenheld, E.G., Puddington, L. & Lefrançois, L. (2008) Avidity maturation of memory CD8 T cells is limited by self-antigen expression. The Journal of Experimental Medicine, 205, 1859-1868.
46. Van Dijk, J.P., Knops, G.H.J.N., Van De Locht, L.T.F., Menke, A.L., Jansen, J.H., Mensink, E.J.B.M., Raymakers, R.A.P. & De Witte, T. (2002) Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow. British Journal of Haematology, 118, 1027-1033.
47. Walker, E.B., Haley, D., Petrausch, U., Floyd, K., Miller, W., Sanjuan, N., Alvord, G., Fox, B.A. & Urba, W.J. (2008) Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Clinical Cancer Research, 14, 5270-5283.
48. Yang, S., Linette, G.P., Longerich, S. & Haluska, F.G. (2002) Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. Journal of Immunology (Baltimore, Md.: 1950), 169, 531-539.
49. Zeh, H.J., Perry-Lalley, D., Dudley, M.E., Rosenberg, S.A. & Yang, J.C. (1999) High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. Journal of Immunology (Baltimore, Md.: 1950), 162, 989-994.